Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing

Abstract Background Thrombotic microangiopathies (TMA) are serious medical conditions requiring a prompt diagnosis to adapt treatment. The determination of ADAMTS-13 activity enables discriminating thrombotic thrombocytopenic purpura (TTP) from other forms of TMA. The purpose of this study was to pr...

Full description

Bibliographic Details
Published in:Orphanet Journal of Rare Diseases
Main Authors: Clémence Merlen, Emmanuelle Pépin, Ousmane Barry, Anik Cormier, Caroline Dubois, Anne-Laure Lapeyraque, Stéphan Troyanov, Georges-Etienne Rivard, Arnaud Bonnefoy
Format: Article
Language:English
Published: BMC 2022-08-01
Subjects:
Online Access:https://doi.org/10.1186/s13023-022-02409-3
_version_ 1852750620955508736
author Clémence Merlen
Emmanuelle Pépin
Ousmane Barry
Anik Cormier
Caroline Dubois
Anne-Laure Lapeyraque
Stéphan Troyanov
Georges-Etienne Rivard
Arnaud Bonnefoy
author_facet Clémence Merlen
Emmanuelle Pépin
Ousmane Barry
Anik Cormier
Caroline Dubois
Anne-Laure Lapeyraque
Stéphan Troyanov
Georges-Etienne Rivard
Arnaud Bonnefoy
author_sort Clémence Merlen
collection DOAJ
container_title Orphanet Journal of Rare Diseases
description Abstract Background Thrombotic microangiopathies (TMA) are serious medical conditions requiring a prompt diagnosis to adapt treatment. The determination of ADAMTS-13 activity enables discriminating thrombotic thrombocytopenic purpura (TTP) from other forms of TMA. The purpose of this study was to provide an estimate of the incidence of TTP and TMA in the Canadian Quebec province using data collected from a laboratory centralizing ADAMTS-13 testing for the whole province. Results From 2012 to 2019, 846 patients were evaluated for plasma ADAMTS-13 activity due to a suspicion of TMA. TTP was identified in 147 patients. Of these, 118 patients with a median age of 51.5 years and a male–female ratio of 1:1.4 had their first episode of TTP during the study period. The number of ADAMTS-13 tests performed and the number of patients with suspected TMA increased annually by 19% and 21% respectively. While the incidence of non-TTP TMA increased annually, that for TTP remained unchanged. This averaged 10.2 (95% CI 5.9–14.4) per million persons per year for suspected non-TTP TMA and 1.8 (95% CI 1.3–2.4) for confirmed TTP. The incidence rate of TMA other than TTP was higher in the age group 70–79 years (21.8; 95% CI 5.4–38.1) for females and in the age group 80–89 years (24.4; 95% CI 7.2–41.7) for males compared to other age groups. The incidence rate of TTP was higher in the age group 40–49 years (4.0; 95% CI 2.0–5.9) for women and in the age group 60–69 years (3.4; 95% CI 1.1–5.6) for men compared to other age groups. Conclusion The analysis of centralized data measuring ADAMTS-13 activity allowed us to adequately establish the incidence rate and demographic characteristics of TMA, particularly TTP, in Quebec. TTP incidence remained stable while suspected non-TTP TMA steadily increased from 2012 to 2019.
format Article
id doaj-art-b3eea96a95df48bdbae2fd6987d71827
institution Directory of Open Access Journals
issn 1750-1172
language English
publishDate 2022-08-01
publisher BMC
record_format Article
spelling doaj-art-b3eea96a95df48bdbae2fd6987d718272025-08-19T21:00:23ZengBMCOrphanet Journal of Rare Diseases1750-11722022-08-0117111110.1186/s13023-022-02409-3Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testingClémence Merlen0Emmanuelle Pépin1Ousmane Barry2Anik Cormier3Caroline Dubois4Anne-Laure Lapeyraque5Stéphan Troyanov6Georges-Etienne Rivard7Arnaud Bonnefoy8Division of Hematology-Oncology, CHU Sainte-Justine, Université de MontréalDivision of Hematology-Oncology, CHU Sainte-Justine, Université de MontréalDivision of Hematology-Oncology, CHU Sainte-Justine, Université de MontréalDepartment of Clinical Laboratory Medicine, OPTILAB Montréal-CHU Sainte-JustineDepartment of Clinical Laboratory Medicine, OPTILAB Montréal-CHU Sainte-JustineDivision of Nephrology, CHU Sainte-Justine, Université de MontréalDivision of Nephrology, Hôpital du Sacré-Cœur, Université de MontréalDivision of Hematology-Oncology, CHU Sainte-Justine, Université de MontréalDivision of Hematology-Oncology, CHU Sainte-Justine, Université de MontréalAbstract Background Thrombotic microangiopathies (TMA) are serious medical conditions requiring a prompt diagnosis to adapt treatment. The determination of ADAMTS-13 activity enables discriminating thrombotic thrombocytopenic purpura (TTP) from other forms of TMA. The purpose of this study was to provide an estimate of the incidence of TTP and TMA in the Canadian Quebec province using data collected from a laboratory centralizing ADAMTS-13 testing for the whole province. Results From 2012 to 2019, 846 patients were evaluated for plasma ADAMTS-13 activity due to a suspicion of TMA. TTP was identified in 147 patients. Of these, 118 patients with a median age of 51.5 years and a male–female ratio of 1:1.4 had their first episode of TTP during the study period. The number of ADAMTS-13 tests performed and the number of patients with suspected TMA increased annually by 19% and 21% respectively. While the incidence of non-TTP TMA increased annually, that for TTP remained unchanged. This averaged 10.2 (95% CI 5.9–14.4) per million persons per year for suspected non-TTP TMA and 1.8 (95% CI 1.3–2.4) for confirmed TTP. The incidence rate of TMA other than TTP was higher in the age group 70–79 years (21.8; 95% CI 5.4–38.1) for females and in the age group 80–89 years (24.4; 95% CI 7.2–41.7) for males compared to other age groups. The incidence rate of TTP was higher in the age group 40–49 years (4.0; 95% CI 2.0–5.9) for women and in the age group 60–69 years (3.4; 95% CI 1.1–5.6) for men compared to other age groups. Conclusion The analysis of centralized data measuring ADAMTS-13 activity allowed us to adequately establish the incidence rate and demographic characteristics of TMA, particularly TTP, in Quebec. TTP incidence remained stable while suspected non-TTP TMA steadily increased from 2012 to 2019.https://doi.org/10.1186/s13023-022-02409-3Thrombotic microangiopathiesThrombotic thrombocytopenic purpuraADAMTS-13IncidenceEpidemiologyPrevalence
spellingShingle Clémence Merlen
Emmanuelle Pépin
Ousmane Barry
Anik Cormier
Caroline Dubois
Anne-Laure Lapeyraque
Stéphan Troyanov
Georges-Etienne Rivard
Arnaud Bonnefoy
Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing
Thrombotic microangiopathies
Thrombotic thrombocytopenic purpura
ADAMTS-13
Incidence
Epidemiology
Prevalence
title Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing
title_full Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing
title_fullStr Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing
title_full_unstemmed Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing
title_short Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing
title_sort incidence of thrombotic microangiopathies in quebec insight from a laboratory centralizing adamts 13 testing
topic Thrombotic microangiopathies
Thrombotic thrombocytopenic purpura
ADAMTS-13
Incidence
Epidemiology
Prevalence
url https://doi.org/10.1186/s13023-022-02409-3
work_keys_str_mv AT clemencemerlen incidenceofthromboticmicroangiopathiesinquebecinsightfromalaboratorycentralizingadamts13testing
AT emmanuellepepin incidenceofthromboticmicroangiopathiesinquebecinsightfromalaboratorycentralizingadamts13testing
AT ousmanebarry incidenceofthromboticmicroangiopathiesinquebecinsightfromalaboratorycentralizingadamts13testing
AT anikcormier incidenceofthromboticmicroangiopathiesinquebecinsightfromalaboratorycentralizingadamts13testing
AT carolinedubois incidenceofthromboticmicroangiopathiesinquebecinsightfromalaboratorycentralizingadamts13testing
AT annelaurelapeyraque incidenceofthromboticmicroangiopathiesinquebecinsightfromalaboratorycentralizingadamts13testing
AT stephantroyanov incidenceofthromboticmicroangiopathiesinquebecinsightfromalaboratorycentralizingadamts13testing
AT georgesetiennerivard incidenceofthromboticmicroangiopathiesinquebecinsightfromalaboratorycentralizingadamts13testing
AT arnaudbonnefoy incidenceofthromboticmicroangiopathiesinquebecinsightfromalaboratorycentralizingadamts13testing